Chemo-free regimen appears viable in previously untreated FL

Second primary malignancies occurred in 7% of patients in the R² arm and 10% of the R-chemotherapy arm.

The study was sponsored was Celgene and the Lymphoma Academic Research Organisation. Dr. Fowler reported disclosures related to Abbvie, Celgene, Janssen, Merck, and Roche.

SOURCE: Fowler NH et al. ASCO 2018, Abstract 7500.